ID   ZAP70_HUMAN             Reviewed;         619 AA.
AC   P43403; A6NFP4; Q6PIA4; Q8IXD6; Q9UBS6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   12-OCT-2022, entry version 239.
DE   RecName: Full=Tyrosine-protein kinase ZAP-70;
DE            EC=2.7.10.2;
DE   AltName: Full=70 kDa zeta-chain associated protein;
DE   AltName: Full=Syk-related tyrosine kinase;
GN   Name=ZAP70; Synonyms=SRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH CD247,
RP   TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=1423621; DOI=10.1016/0092-8674(92)90598-7;
RA   Chan A.C., Iwashima M., Turck C.W., Weiss A.;
RT   "ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta
RT   chain.";
RL   Cell 71:649-662(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Leukocyte;
RX   PubMed=14985102; DOI=10.1016/j.bbrc.2004.01.127;
RA   Kuroyama H., Ikeda T., Kasai M., Yamasaki S., Tatsumi M., Utsuyama M.,
RA   Saito T., Hirokawa K.;
RT   "Identification of a novel isoform of ZAP-70, truncated ZAP kinase.";
RL   Biochem. Biophys. Res. Commun. 315:935-941(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Blood, and Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 521-547, VARIANT IMD48 LEU-GLU-GLN-541 INS,
RP   FUNCTION, AND INVOLVEMENT IN IMD48.
RC   TISSUE=Lymphoid tissue;
RX   PubMed=8124727; DOI=10.1016/0092-8674(94)90368-9;
RA   Arpaia E., Shahar M., Dadi H., Cohen A., Roifman C.M.;
RT   "Defective T cell receptor signaling and CD8+ thymic selection in humans
RT   lacking zap-70 kinase.";
RL   Cell 76:947-958(1994).
RN   [6]
RP   CHARACTERIZATION OF TAM-BINDING.
RX   PubMed=7528772; DOI=10.1084/jem.181.1.375;
RA   Isakov N., Wange R.L., Burgess W.H., Watts J.D., Aebersold R.,
RA   Samelson L.E.;
RT   "ZAP-70 binding specificity to T cell receptor tyrosine-based activation
RT   motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based
RT   activation motifs with varying affinity.";
RL   J. Exp. Med. 181:375-380(1995).
RN   [7]
RP   PHOSPHORYLATION AT TYR-492 AND TYR-493, AND MUTAGENESIS OF TYR-492 AND
RP   TYR-493.
RX   PubMed=7781602; DOI=10.1002/j.1460-2075.1995.tb07247.x;
RA   Chan A.C., Dalton M., Johnson R., Kong G.H., Wang T., Thoma R.,
RA   Kurosaki T.;
RT   "Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is
RT   required for lymphocyte antigen receptor function.";
RL   EMBO J. 14:2499-2508(1995).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF LCP2.
RX   PubMed=8702662; DOI=10.1074/jbc.271.33.19641;
RA   Bubeck Wardenburg J., Fu C., Jackman J.K., Flotow H., Wilkinson S.E.,
RA   Williams D.H., Johnson R., Kong G., Chan A.C., Findell P.R.;
RT   "Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is
RT   required for T-cell receptor function.";
RL   J. Biol. Chem. 271:19641-19644(1996).
RN   [9]
RP   PHOSPHORYLATION AT TYR-292, AND MUTAGENESIS OF TYR-292.
RX   PubMed=8943331; DOI=10.1128/mcb.16.12.6765;
RA   Zhao Q., Weiss A.;
RT   "Enhancement of lymphocyte responsiveness by a gain-of-function mutation of
RT   ZAP-70.";
RL   Mol. Cell. Biol. 16:6765-6774(1996).
RN   [10]
RP   INTERACTION WITH VAV1, AND MUTAGENESIS OF TYR-315.
RX   PubMed=9151714; DOI=10.1084/jem.185.10.1877;
RA   Wu J., Zhao Q., Kurosaki T., Weiss A.;
RT   "The Vav binding site (Y315) in ZAP-70 is critical for antigen receptor-
RT   mediated signal transduction.";
RL   J. Exp. Med. 185:1877-1882(1997).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=9378960;
RA   Gary-Gouy H., Lang V., Sarun S., Boumsell L., Bismuth G.;
RT   "In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and p21
RT   phospho-zeta molecules in human CD3+ thymocytes.";
RL   J. Immunol. 159:3739-3747(1997).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF LAT.
RX   PubMed=9489702; DOI=10.1016/s0092-8674(00)80901-0;
RA   Zhang W., Sloan-Lancaster J., Kitchen J., Trible R.P., Samelson L.E.;
RT   "LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to
RT   cellular activation.";
RL   Cell 92:83-92(1998).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9813084; DOI=10.1083/jcb.143.3.613;
RA   Sloan-Lancaster J., Presley J., Ellenberg J., Yamazaki T.,
RA   Lippincott-Schwartz J., Samelson L.E.;
RT   "ZAP-70 association with T cell receptor zeta (TCRzeta): fluorescence
RT   imaging of dynamic changes upon cellular stimulation.";
RL   J. Cell Biol. 143:613-624(1998).
RN   [14]
RP   PHOSPHORYLATION AT TYR-315 AND TYR-319, AND MUTAGENESIS OF TYR-315 AND
RP   TYR-319.
RX   PubMed=10037717; DOI=10.1074/jbc.274.10.6285;
RA   Di Bartolo V., Mege D., Germain V., Pelosi M., Dufour E., Michel F.,
RA   Magistrelli G., Isacchi A., Acuto O.;
RT   "Tyrosine 319, a newly identified phosphorylation site of ZAP-70, plays a
RT   critical role in T cell antigen receptor signaling.";
RL   J. Biol. Chem. 274:6285-6294(1999).
RN   [15]
RP   INTERACTION WITH CBL AND SLA.
RX   PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [16]
RP   FUNCTION IN CD3Z UBIQUITINATION.
RX   PubMed=11353765; DOI=10.1074/jbc.m010738200;
RA   Wang H.Y., Altman Y., Fang D., Elly C., Dai Y., Shao Y., Liu Y.C.;
RT   "Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor
RT   function of Zap-70.";
RL   J. Biol. Chem. 276:26004-26011(2001).
RN   [17]
RP   INTERACTION WITH FCRL3.
RX   PubMed=12051764; DOI=10.1016/s0006-291x(02)00332-7;
RA   Xu M.-J., Zhao R., Cao H., Zhao Z.J.;
RT   "SPAP2, an Ig family receptor containing both ITIMs and ITAMs.";
RL   Biochem. Biophys. Res. Commun. 293:1037-1046(2002).
RN   [18]
RP   MUTAGENESIS OF TYR-315.
RX   PubMed=11828374;
RX   DOI=10.1002/1521-4141(200202)32:2<568::aid-immu568>3.0.co;2-q;
RA   Di Bartolo V., Malissen M., Dufour E., Sechet E., Malissen B., Acuto O.;
RT   "Tyrosine 315 determines optimal recruitment of ZAP-70 to the T cell
RT   antigen receptor.";
RL   Eur. J. Immunol. 32:568-575(2002).
RN   [19]
RP   INTERACTION WITH SHB.
RX   PubMed=12084069; DOI=10.1046/j.1432-1033.2002.03008.x;
RA   Lindholm C.K., Henriksson M.L., Hallberg B., Welsh M.;
RT   "Shb links SLP-76 and Vav with the CD3 complex in Jurkat T cells.";
RL   Eur. J. Biochem. 269:3279-3288(2002).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C.,
RA   Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using mass
RT   spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [22]
RP   INTERACTION WITH NFAM1.
RX   PubMed=15143214; DOI=10.1073/pnas.0401119101;
RA   Ohtsuka M., Arase H., Takeuchi A., Yamasaki S., Shiina R., Suenaga T.,
RA   Sakurai D., Yokosuka T., Arase N., Iwashima M., Kitamura T., Moriya H.,
RA   Saito T.;
RT   "NFAM1, an immunoreceptor tyrosine-based activation motif-bearing molecule
RT   that regulates B cell development and signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:8126-8131(2004).
RN   [23]
RP   PHOSPHORYLATION BY LCK.
RX   PubMed=16339550; DOI=10.4049/jimmunol.175.12.8123;
RA   Gelkop S., Gish G.D., Babichev Y., Pawson T., Isakov N.;
RT   "T cell activation-induced CrkII binding to the Zap70 protein tyrosine
RT   kinase is mediated by Lck-dependent phosphorylation of Zap70 tyrosine
RT   315.";
RL   J. Immunol. 175:8123-8132(2005).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-248, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [25]
RP   TISSUE SPECIFICITY.
RX   PubMed=16467082; DOI=10.1158/1078-0432.ccr-05-1531;
RA   Crespo M., Villamor N., Gine E., Muntanola A., Colomer D., Marafioti T.,
RA   Jones M., Camos M., Campo E., Montserrat E., Bosch F.;
RT   "ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell
RT   acute lymphoblastic leukemia.";
RL   Clin. Cancer Res. 12:726-734(2006).
RN   [26]
RP   DEPHOSPHORYLATION BY PTN22.
RX   PubMed=16461343; DOI=10.1074/jbc.m600498200;
RA   Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J.,
RA   Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J., Clark J.M.;
RT   "Identification of substrates of human protein-tyrosine phosphatase
RT   PTPN22.";
RL   J. Biol. Chem. 281:11002-11010(2006).
RN   [27]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290920; DOI=10.1111/j.1600-065x.2008.00753.x;
RA   Au-Yeung B.B., Deindl S., Hsu L.Y., Palacios E.H., Levin S.E., Kuriyan J.,
RA   Weiss A.;
RT   "The structure, regulation, and function of ZAP-70.";
RL   Immunol. Rev. 228:41-57(2009).
RN   [28]
RP   INTERACTION WITH FCRL3.
RX   PubMed=19843936; DOI=10.4049/jimmunol.0901982;
RA   Kochi Y., Myouzen K., Yamada R., Suzuki A., Kurosaki T., Nakamura Y.,
RA   Yamamoto K.;
RT   "FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-
RT   cell receptor-mediated signaling.";
RL   J. Immunol. 183:5502-5510(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-292, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-603, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [31]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=20135127; DOI=10.1007/s00281-010-0196-x;
RA   Fischer A., Picard C., Chemin K., Dogniaux S., le Deist F., Hivroz C.;
RT   "ZAP70: a master regulator of adaptive immunity.";
RL   Semin. Immunopathol. 32:107-116(2010).
RN   [32]
RP   FUNCTION, INTERACTION WITH OTUD7B AND UBASH3B, UBIQUITINATION AT LYS-544,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF LYS-304; LYS-538
RP   AND LYS-544.
RX   PubMed=26903241; DOI=10.1084/jem.20151426;
RA   Hu H., Wang H., Xiao Y., Jin J., Chang J.H., Zou Q., Xie X., Cheng X.,
RA   Sun S.C.;
RT   "Otud7b facilitates T cell activation and inflammatory responses by
RT   regulating Zap70 ubiquitination.";
RL   J. Exp. Med. 213:399-414(2016).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 3-256 IN COMPLEX WITH CD247, AND
RP   INTERACTION WITH CD247.
RX   PubMed=7659156; DOI=10.1038/377032a0;
RA   Hatada M.H., Lu X., Laird E.R., Green J., Morgenstern J.P., Lou M.,
RA   Marr C.S., Phillips T.B., Ram M.K., Theriault K., Zoller M.J., Karas L.K.;
RT   "Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with
RT   the T-cell receptor.";
RL   Nature 377:32-38(1995).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 286-297 IN COMPLEX WITH CBL, AND
RP   INTERACTION WITH CBL.
RX   PubMed=10078535; DOI=10.1038/18050;
RA   Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J.;
RT   "Structure of the amino-terminal domain of Cbl complexed to its binding
RT   site on ZAP-70 kinase.";
RL   Nature 398:84-90(1999).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 289-297 IN COMPLEX WITH CBL AND
RP   UBE2L3.
RX   PubMed=10966114; DOI=10.1016/s0092-8674(00)00057-x;
RA   Zheng N., Wang P., Jeffrey P.D., Pavletich N.P.;
RT   "Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-
RT   protein ligases.";
RL   Cell 102:533-539(2000).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-256.
RX   PubMed=12450381; DOI=10.1021/bi026465e;
RA   Folmer R.H., Geschwindner S., Xue Y.;
RT   "Crystal structure and NMR studies of the apo SH2 domains of ZAP-70: two
RT   bikes rather than a tandem.";
RL   Biochemistry 41:14176-14184(2002).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 327-606 IN COMPLEX WITH
RP   STAUROSPORINE, CATALYTIC ACTIVITY, ACTIVE SITE, MUTAGENESIS OF ASP-479, AND
RP   ACTIVITY REGULATION.
RX   PubMed=15292186; DOI=10.1074/jbc.m407096200;
RA   Jin L., Pluskey S., Petrella E.C., Cantin S.M., Gorga J.C.,
RA   Rynkiewicz M.J., Pandey P., Strickler J.E., Babine R.E., Weaver D.T.,
RA   Seidl K.J.;
RT   "The three-dimensional structure of the ZAP-70 kinase domain in complex
RT   with staurosporine: implications for the design of selective inhibitors.";
RL   J. Biol. Chem. 279:42818-42825(2004).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-606 OF MUTANT ASN-461 IN COMPLEX
RP   WITH MAGNESIUM AND ATP ANALOG, ACTIVE SITE, AND MUTAGENESIS OF TRP-131;
RP   LEU-133; ALA-141; SER-144; GLN-145; PRO-147; TYR-315; TYR-319; ASP-461;
RP   TYR-597 AND TYR-598.
RX   PubMed=17512407; DOI=10.1016/j.cell.2007.03.039;
RA   Deindl S., Kadlecek T.A., Brdicka T., Cao X., Weiss A., Kuriyan J.;
RT   "Structural basis for the inhibition of tyrosine kinase activity of
RT   ZAP-70.";
RL   Cell 129:735-746(2007).
RN   [39]
RP   VARIANT IMD48 ARG-518.
RX   PubMed=8202713; DOI=10.1126/science.8202713;
RA   Chan A.C., Kadlecek T.A., Elder M.E., Filipovich A.H., Kuo W.-L.,
RA   Iwashima M., Parslow T.G., Weiss A.;
RT   "ZAP-70 deficiency in an autosomal recessive form of severe combined
RT   immunodeficiency.";
RL   Science 264:1599-1601(1994).
RN   [40]
RP   VARIANT IMD48 HIS-465.
RX   PubMed=11412303; DOI=10.1046/j.1365-2567.2001.01246.x;
RA   Toyabe S., Watanabe A., Harada W., Karasawa T., Uchiyama M.;
RT   "Specific immunoglobulin E responses in ZAP-70-deficient patients are
RT   mediated by Syk-dependent T-cell receptor signalling.";
RL   Immunology 103:164-171(2001).
RN   [41]
RP   VARIANT IMD48 CYS-465.
RX   PubMed=11123350; DOI=10.4049/jimmunol.166.1.656;
RA   Elder M.E., Skoda-Smith S., Kadlecek T.A., Wang F., Wu J., Weiss A.;
RT   "Distinct T cell developmental consequences in humans and mice expressing
RT   identical mutations in the DLAARN motif of ZAP-70.";
RL   J. Immunol. 166:656-661(2001).
RN   [42]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-175; LEU-191; GLU-448 AND LEU-523.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [43]
RP   VARIANTS IMD48 ARG-337; VAL-507 AND ARG-564.
RX   PubMed=18509675; DOI=10.1007/s00431-008-0718-x;
RA   Turul T., Tezcan I., Artac H., de Bruin-Versteeg S., Barendregt B.H.,
RA   Reisli I., Sanal O., van Dongen J.J., van der Burg M.;
RT   "Clinical heterogeneity can hamper the diagnosis of patients with ZAP70
RT   deficiency.";
RL   Eur. J. Pediatr. 168:87-93(2009).
RN   [44]
RP   VARIANTS ADMIO2 TRP-192 AND PRO-360, CHARACTERIZATION OF VARIANTS ADMIO2
RP   TRP-192 AND PRO-360, INVOLVEMENT IN ADMIO2, INTERACTION WITH CD247, AND
RP   MUTAGENESIS OF ARG-37; ARG-190; 315-TYR--TYR-319; ASP-327 AND LYS-362.
RX   PubMed=26783323; DOI=10.1084/jem.20150888;
RA   Chan A.Y., Punwani D., Kadlecek T.A., Cowan M.J., Olson J.L., Mathes E.F.,
RA   Sunderam U., Fu S.M., Srinivasan R., Kuriyan J., Brenner S.E., Weiss A.,
RA   Puck J.M.;
RT   "A novel human autoimmune syndrome caused by combined hypomorphic and
RT   activating mutations in ZAP-70.";
RL   J. Exp. Med. 213:155-165(2016).
CC   -!- FUNCTION: Tyrosine kinase that plays an essential role in regulation of
CC       the adaptive immune response. Regulates motility, adhesion and cytokine
CC       expression of mature T-cells, as well as thymocyte development.
CC       Contributes also to the development and activation of primary B-
CC       lymphocytes. When antigen presenting cells (APC) activate T-cell
CC       receptor (TCR), a serie of phosphorylations lead to the recruitment of
CC       ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through
CC       ITAM motif at the plasma membrane. This recruitment serves to
CC       localization to the stimulated TCR and to relieve its autoinhibited
CC       conformation. Release of ZAP70 active conformation is further
CC       stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70
CC       phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In
CC       turn, a large number of signaling molecules are recruited and
CC       ultimately lead to lymphokine production, T-cell proliferation and
CC       differentiation. Furthermore, ZAP70 controls cytoskeleton
CC       modifications, adhesion and mobility of T-lymphocytes, thus ensuring
CC       correct delivery of effectors to the APC. ZAP70 is also required for
CC       TCR-CD247/CD3Z internalization and degradation through interaction with
CC       the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2.
CC       Thus, ZAP70 regulates both T-cell activation switch on and switch off
CC       by modulating TCR expression at the T-cell surface. During thymocyte
CC       development, ZAP70 promotes survival and cell-cycle progression of
CC       developing thymocytes before positive selection (when cells are still
CC       CD4/CD8 double negative). Additionally, ZAP70-dependent signaling
CC       pathway may also contribute to primary B-cells formation and activation
CC       through B-cell receptor (BCR). {ECO:0000269|PubMed:11353765,
CC       ECO:0000269|PubMed:12051764, ECO:0000269|PubMed:1423621,
CC       ECO:0000269|PubMed:20135127, ECO:0000269|PubMed:26903241,
CC       ECO:0000269|PubMed:8124727, ECO:0000269|PubMed:8702662,
CC       ECO:0000269|PubMed:9489702}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:15292186};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation at Tyr-493 in the
CC       activation loop. Inhibited by staurosporine.
CC       {ECO:0000269|PubMed:15292186}.
CC   -!- SUBUNIT: Interacts with CD247/CD3Z; this interaction docks ZAP70 at the
CC       stimulated TCR (PubMed:1423621, PubMed:7659156, PubMed:26783323).
CC       Interacts with NFAM1 (PubMed:15143214). Interacts with adapter protein
CC       SLA; this interaction negatively regulates T-cell receptor signaling
CC       (PubMed:10449770). Interacts with FCRL3 (PubMed:12051764,
CC       PubMed:19843936). Interacts with VAV1 (PubMed:9151714). Interacts with
CC       CBL; this interaction promotes ubiquitination, internalization and
CC       subsequent degradation of CD247/CD3Z (PubMed:10449770,
CC       PubMed:10078535). Identified in a complex with CBL and UBE2L3
CC       (PubMed:10966114). Interacts with SHB (PubMed:12084069). Interacts with
CC       adapter protein SLA2; this interaction negatively regulates T-cell
CC       receptor signaling. Interacts with CBLB. Interacts (via SH2 domains)
CC       with RHOH; this interaction regulates ZAP70 subcellular localization.
CC       Interacts with DEF6 (By similarity). Interacts (ubiquitinated form)
CC       with OTUD7B and UBASH3B (PubMed:26903241).
CC       {ECO:0000250|UniProtKB:P43404, ECO:0000269|PubMed:10078535,
CC       ECO:0000269|PubMed:10449770, ECO:0000269|PubMed:10966114,
CC       ECO:0000269|PubMed:12051764, ECO:0000269|PubMed:12084069,
CC       ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:15143214,
CC       ECO:0000269|PubMed:19843936, ECO:0000269|PubMed:26783323,
CC       ECO:0000269|PubMed:26903241, ECO:0000269|PubMed:7659156,
CC       ECO:0000269|PubMed:9151714}.
CC   -!- INTERACTION:
CC       P43403; P22681: CBL; NbExp=3; IntAct=EBI-1211276, EBI-518228;
CC       P43403; P20963: CD247; NbExp=23; IntAct=EBI-1211276, EBI-1165705;
CC       P43403; P07766: CD3E; NbExp=3; IntAct=EBI-1211276, EBI-1211297;
CC       P43403; P00533: EGFR; NbExp=3; IntAct=EBI-1211276, EBI-297353;
CC       P43403; P10721: KIT; NbExp=2; IntAct=EBI-1211276, EBI-1379503;
CC       P43403; P06239: LCK; NbExp=2; IntAct=EBI-1211276, EBI-1348;
CC       P43403; P08581: MET; NbExp=2; IntAct=EBI-1211276, EBI-1039152;
CC       P43403; Q9Y2R2: PTPN22; NbExp=4; IntAct=EBI-1211276, EBI-1211241;
CC       P43403; Q8N1K5-1: THEMIS; NbExp=3; IntAct=EBI-1211276, EBI-15102259;
CC       P43403; Q8BGG7: Ubash3b; Xeno; NbExp=10; IntAct=EBI-1211276, EBI-8846415;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9813084}. Cell
CC       membrane {ECO:0000269|PubMed:9813084}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9813084}. Note=In quiescent T-lymphocytes, it is
CC       cytoplasmic. Upon TCR activation, it is recruited at the plasma
CC       membrane by interacting with CD247/CD3Z. Colocalizes together with RHOH
CC       in the immunological synapse. RHOH is required for its proper
CC       localization to the cell membrane and cytoskeleton fractions in the
CC       thymocytes (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P43403-1; Sequence=Displayed;
CC       Name=2; Synonyms=TZK;
CC         IsoId=P43403-2; Sequence=VSP_031156;
CC       Name=3;
CC         IsoId=P43403-3; Sequence=VSP_031157, VSP_031158;
CC   -!- TISSUE SPECIFICITY: Expressed in T- and natural killer cells. Also
CC       present in early thymocytes and pro/pre B-cells.
CC       {ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:16467082,
CC       ECO:0000269|PubMed:9378960}.
CC   -!- DOMAIN: Composed of 2 N-terminal SH2 domains and a C-terminal kinase
CC       domain. The tandem SH2 domains bind to the doubly phosphorylated
CC       tyrosine-based activation motif (ITAM) of CD247/CD3Z and the non-
CC       canonical phosphorylated tyrosine-based activation motif (TAM) of RHOH
CC       (By similarity). The interdomain B located between the second SH2 and
CC       the kinase domain contains 3 tyrosines (Tyr-292, Tyr-315, Tyr-319) that
CC       are phosphorylated following TCR activation. These sites have been
CC       implicated in binding to other signaling molecules including CBL or
CC       VAV1. Thus, ZAP70 can also function as a scaffold by recruiting
CC       additional factors to the stimulated TCR complex. {ECO:0000250,
CC       ECO:0000269|PubMed:20135127}.
CC   -!- PTM: Phosphorylated on tyrosine residues upon T-cell antigen receptor
CC       (TCR) stimulation. Phosphorylation of Tyr-315 and Tyr-319 are essential
CC       for ZAP70 positive function on T-lymphocyte activation whereas Tyr-292
CC       has a negative regulatory role. Within the C-terminal kinase domain,
CC       Tyr-492 and Tyr-493 are phosphorylated after TCR induction, Tyr-492
CC       playing a negative regulatory role and Tyr-493 a positive. Tyr-493 is
CC       dephosphorylated by PTN22. {ECO:0000269|PubMed:10037717,
CC       ECO:0000269|PubMed:1423621, ECO:0000269|PubMed:16339550,
CC       ECO:0000269|PubMed:8943331}.
CC   -!- PTM: Ubiquitinated in response to T cell activation. Deubiquitinated by
CC       OTUD7B. {ECO:0000269|PubMed:26903241}.
CC   -!- DISEASE: Immunodeficiency 48 (IMD48) [MIM:269840]: A form of severe
CC       immunodeficiency characterized by a selective absence of CD8+ T-cells.
CC       {ECO:0000269|PubMed:11123350, ECO:0000269|PubMed:11412303,
CC       ECO:0000269|PubMed:18509675, ECO:0000269|PubMed:8124727,
CC       ECO:0000269|PubMed:8202713}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Autoimmune disease, multisystem, infantile-onset, 2 (ADMIO2)
CC       [MIM:617006]: An autosomal recessive, autoimmune disorder characterized
CC       by systemic manifestations including blistering skin disease,
CC       uncontrollable bullous pemphigoid, inflammatory colitis, autoimmune
CC       hypothyroidism, proteinuria and nephrotic syndrome.
CC       {ECO:0000269|PubMed:26783323}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SYK/ZAP-70 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=ZAP70base; Note=ZAP70 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/ZAP70base/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L05148; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AB083211; BAC43747.1; -; mRNA.
DR   EMBL; AC016699; AAX93187.1; -; Genomic_DNA.
DR   EMBL; BC039039; AAH39039.1; -; mRNA.
DR   EMBL; BC053878; AAH53878.1; -; mRNA.
DR   CCDS; CCDS33254.1; -. [P43403-1]
DR   CCDS; CCDS33255.1; -. [P43403-2]
DR   PIR; A44266; A44266.
DR   PIR; A49955; A49955.
DR   RefSeq; NP_001070.2; NM_001079.3. [P43403-1]
DR   RefSeq; NP_997402.1; NM_207519.1. [P43403-2]
DR   PDB; 1FBV; X-ray; 2.90 A; B=289-297.
DR   PDB; 1M61; X-ray; 2.50 A; A=1-256.
DR   PDB; 1U59; X-ray; 2.30 A; A=327-606.
DR   PDB; 2CBL; X-ray; 2.10 A; B=286-297.
DR   PDB; 2OQ1; X-ray; 1.90 A; A=3-256.
DR   PDB; 2OZO; X-ray; 2.60 A; A=1-606.
DR   PDB; 2Y1N; X-ray; 2.00 A; B/D=286-297.
DR   PDB; 3ZNI; X-ray; 2.21 A; B/F/J/N=286-297.
DR   PDB; 4A4B; X-ray; 2.79 A; B=286-297.
DR   PDB; 4A4C; X-ray; 2.70 A; B=286-297.
DR   PDB; 4K2R; X-ray; 3.00 A; A=1-606.
DR   PDB; 4XZ0; X-ray; 2.00 A; A=1-259.
DR   PDB; 4XZ1; X-ray; 2.80 A; A=1-259.
DR   PDB; 5O76; X-ray; 2.47 A; B/D=286-297.
DR   PDBsum; 1FBV; -.
DR   PDBsum; 1M61; -.
DR   PDBsum; 1U59; -.
DR   PDBsum; 2CBL; -.
DR   PDBsum; 2OQ1; -.
DR   PDBsum; 2OZO; -.
DR   PDBsum; 2Y1N; -.
DR   PDBsum; 3ZNI; -.
DR   PDBsum; 4A4B; -.
DR   PDBsum; 4A4C; -.
DR   PDBsum; 4K2R; -.
DR   PDBsum; 4XZ0; -.
DR   PDBsum; 4XZ1; -.
DR   PDBsum; 5O76; -.
DR   AlphaFoldDB; P43403; -.
DR   SMR; P43403; -.
DR   BioGRID; 113367; 69.
DR   CORUM; P43403; -.
DR   DIP; DIP-38781N; -.
DR   ELM; P43403; -.
DR   IntAct; P43403; 76.
DR   MINT; P43403; -.
DR   STRING; 9606.ENSP00000264972; -.
DR   BindingDB; P43403; -.
DR   ChEMBL; CHEMBL2803; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugCentral; P43403; -.
DR   GuidetoPHARMACOLOGY; 2285; -.
DR   GlyGen; P43403; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P43403; -.
DR   MetOSite; P43403; -.
DR   PhosphoSitePlus; P43403; -.
DR   BioMuta; ZAP70; -.
DR   DMDM; 1177044; -.
DR   jPOST; P43403; -.
DR   MassIVE; P43403; -.
DR   MaxQB; P43403; -.
DR   PaxDb; P43403; -.
DR   PeptideAtlas; P43403; -.
DR   PRIDE; P43403; -.
DR   ProteomicsDB; 55631; -. [P43403-1]
DR   ProteomicsDB; 55632; -. [P43403-2]
DR   ProteomicsDB; 55633; -. [P43403-3]
DR   Antibodypedia; 685; 2245 antibodies from 49 providers.
DR   CPTC; P43403; 1 antibody.
DR   DNASU; 7535; -.
DR   Ensembl; ENST00000264972.10; ENSP00000264972.5; ENSG00000115085.14. [P43403-1]
DR   Ensembl; ENST00000451498.2; ENSP00000400475.2; ENSG00000115085.14. [P43403-2]
DR   GeneID; 7535; -.
DR   KEGG; hsa:7535; -.
DR   MANE-Select; ENST00000264972.10; ENSP00000264972.5; NM_001079.4; NP_001070.2.
DR   UCSC; uc002syd.2; human. [P43403-1]
DR   CTD; 7535; -.
DR   DisGeNET; 7535; -.
DR   GeneCards; ZAP70; -.
DR   GeneReviews; ZAP70; -.
DR   HGNC; HGNC:12858; ZAP70.
DR   HPA; ENSG00000115085; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; ZAP70; -.
DR   MIM; 176947; gene.
DR   MIM; 269840; phenotype.
DR   MIM; 617006; phenotype.
DR   neXtProt; NX_P43403; -.
DR   OpenTargets; ENSG00000115085; -.
DR   Orphanet; 911; Combined immunodeficiency due to ZAP70 deficiency.
DR   PharmGKB; PA37447; -.
DR   VEuPathDB; HostDB:ENSG00000115085; -.
DR   eggNOG; ENOG502QT06; Eukaryota.
DR   GeneTree; ENSGT00940000159185; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P43403; -.
DR   OMA; ACPNTSA; -.
DR   OrthoDB; 827472at2759; -.
DR   PhylomeDB; P43403; -.
DR   TreeFam; TF351629; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P43403; -.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-9013407; RHOH GTPase cycle.
DR   SignaLink; P43403; -.
DR   SIGNOR; P43403; -.
DR   BioGRID-ORCS; 7535; 10 hits in 1101 CRISPR screens.
DR   ChiTaRS; ZAP70; human.
DR   EvolutionaryTrace; P43403; -.
DR   GeneWiki; ZAP70; -.
DR   GenomeRNAi; 7535; -.
DR   Pharos; P43403; Tchem.
DR   PRO; PR:P43403; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P43403; protein.
DR   Bgee; ENSG00000115085; Expressed in granulocyte and 109 other tissues.
DR   Genevisible; P43403; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:HGNC-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0001772; C:immunological synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0042101; C:T cell receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IMP:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0043366; P:beta selection; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0006955; P:immune response; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; IDA:MGI.
DR   GO; GO:0045059; P:positive thymic T cell selection; IDA:MGI.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0070489; P:T cell aggregation; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; NAS:UniProtKB.
DR   GO; GO:0072678; P:T cell migration; TAS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd09938; SH2_N-SH2_Zap70_Syk_like; 1.
DR   DisProt; DP01123; -.
DR   Gene3D; 1.10.930.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 2.
DR   IDEAL; IID00553; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR023420; Kinase_SYK/ZAP-70_inter-SH2_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR035838; SYK/ZAP-70_N_SH2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR012234; Tyr_kinase_non-rcpt_SYK/ZAP70.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PIRSF; PIRSF000604; TyrPK_SYK; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   ATP-binding; Cell membrane; Cytoplasm; Disease variant; Immunity;
KW   Isopeptide bond; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Repeat; SCID; SH2 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   CHAIN           1..619
FT                   /note="Tyrosine-protein kinase ZAP-70"
FT                   /id="PRO_0000088168"
FT   DOMAIN          10..102
FT                   /note="SH2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          163..254
FT                   /note="SH2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          338..600
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          103..162
FT                   /note="Interdomain A"
FT   REGION          255..337
FT                   /note="Interdomain B"
FT   REGION          260..309
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        274..288
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        461
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028,
FT                   ECO:0000269|PubMed:15292186, ECO:0000269|PubMed:17512407"
FT   BINDING         345..352
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         369
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         248
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         289
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186"
FT   MOD_RES         292
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:8943331,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         315
FT                   /note="Phosphotyrosine; by LCK"
FT                   /evidence="ECO:0000269|PubMed:10037717"
FT   MOD_RES         319
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10037717"
FT   MOD_RES         492
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:7781602"
FT   MOD_RES         493
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:7781602"
FT   MOD_RES         603
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CROSSLNK        544
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:26903241"
FT   VAR_SEQ         1..307
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14985102"
FT                   /id="VSP_031156"
FT   VAR_SEQ         1..126
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_031157"
FT   VAR_SEQ         127..134
FT                   /note="VRQTWKLE -> MRLGPRWK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_031158"
FT   VARIANT         175
FT                   /note="R -> L (in dbSNP:rs55964305)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041846"
FT   VARIANT         191
FT                   /note="P -> L (in dbSNP:rs56403250)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041847"
FT   VARIANT         192
FT                   /note="R -> W (in ADMIO2; decreases interaction with
FT                   phosphorylated CD247; decreases ZAP70 phosphorylation; no
FT                   effect on subcellular localization of CD69 at the cell
FT                   surface; dbSNP:rs199840952)"
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT                   /id="VAR_077137"
FT   VARIANT         337
FT                   /note="L -> R (in IMD48; dbSNP:rs1254428002)"
FT                   /evidence="ECO:0000269|PubMed:18509675"
FT                   /id="VAR_065623"
FT   VARIANT         360
FT                   /note="R -> P (in ADMIO2; no effect on interaction with
FT                   phosphorylated CD247; increases TCR-induced Y-319 and Y-493
FT                   phosphorylation of ZAP70 and phosphorylation of LAT and
FT                   LCP2; increases subcellular localization of CD69 at the
FT                   cell surface; weakly decreases autoinhibition conformation;
FT                   dbSNP:rs869025224)"
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT                   /id="VAR_077138"
FT   VARIANT         448
FT                   /note="G -> E (in a head and neck squamous cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041848"
FT   VARIANT         465
FT                   /note="R -> C (in IMD48; dbSNP:rs113994174)"
FT                   /evidence="ECO:0000269|PubMed:11123350"
FT                   /id="VAR_065624"
FT   VARIANT         465
FT                   /note="R -> H (in IMD48; dbSNP:rs137853201)"
FT                   /evidence="ECO:0000269|PubMed:11412303"
FT                   /id="VAR_015538"
FT   VARIANT         507
FT                   /note="A -> V (in IMD48)"
FT                   /evidence="ECO:0000269|PubMed:18509675"
FT                   /id="VAR_065625"
FT   VARIANT         518
FT                   /note="S -> R (in IMD48; dbSNP:rs104893674)"
FT                   /evidence="ECO:0000269|PubMed:8202713"
FT                   /id="VAR_006351"
FT   VARIANT         523
FT                   /note="W -> L (in dbSNP:rs56189815)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041849"
FT   VARIANT         541
FT                   /note="K -> KLEQ (in IMD48)"
FT                   /evidence="ECO:0000269|PubMed:8124727"
FT                   /id="VAR_038688"
FT   VARIANT         564
FT                   /note="C -> R (in IMD48)"
FT                   /evidence="ECO:0000269|PubMed:18509675"
FT                   /id="VAR_065626"
FT   MUTAGEN         37
FT                   /note="R->K: Decreases interaction with phosphorylated
FT                   CD247; when associated with K-190."
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT   MUTAGEN         131
FT                   /note="W->A: Increased constitutive kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         133
FT                   /note="L->A: Increased constitutive kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         141
FT                   /note="A->E: Increased constitutive kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         144
FT                   /note="S->A: Increased kinase activity after activation by
FT                   LCK."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         145
FT                   /note="Q->A: Increased kinase activity after activation by
FT                   LCK."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         147
FT                   /note="P->A: Increased kinase activity after activation by
FT                   LCK."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         190
FT                   /note="R->K: Decreases interaction with phosphorylated
FT                   CD247; when associated with K-37."
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT   MUTAGEN         292
FT                   /note="Y->F: Induces constitutive TCR
FT                   stimulation-independent NFAT induction."
FT                   /evidence="ECO:0000269|PubMed:8943331"
FT   MUTAGEN         304
FT                   /note="K->R: No effect on ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:26903241"
FT   MUTAGEN         314
FT                   /note="V->A: Increased constitutive kinase activity."
FT   MUTAGEN         315..319
FT                   /note="YESPY->AESPA: Increases strongly constitutive kinase
FT                   activity on LAT phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT   MUTAGEN         315
FT                   /note="Y->A: Increased constitutive kinase activity; when
FT                   associated with F-319."
FT                   /evidence="ECO:0000269|PubMed:10037717,
FT                   ECO:0000269|PubMed:11828374, ECO:0000269|PubMed:17512407,
FT                   ECO:0000269|PubMed:9151714"
FT   MUTAGEN         315
FT                   /note="Y->F: Increased constitutive kinase activity; when
FT                   associated with F-319. About 75% loss of CD247/CD3Z-binding
FT                   in stimulated TCR and complete loss of VAV1 interaction."
FT                   /evidence="ECO:0000269|PubMed:10037717,
FT                   ECO:0000269|PubMed:11828374, ECO:0000269|PubMed:17512407,
FT                   ECO:0000269|PubMed:9151714"
FT   MUTAGEN         319
FT                   /note="Y->A: Increased constitutive kinase activity; when
FT                   associated with F-315."
FT                   /evidence="ECO:0000269|PubMed:10037717,
FT                   ECO:0000269|PubMed:17512407"
FT   MUTAGEN         319
FT                   /note="Y->F: Increased constitutive kinase activity; when
FT                   associated with F-315. About 80% loss of TCR-induced NFAT
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:10037717,
FT                   ECO:0000269|PubMed:17512407"
FT   MUTAGEN         327
FT                   /note="D->P: Increases constitutive kinase activity on LAT
FT                   phosphorylation, strongly increases subcellular
FT                   localization of CD69 at the cell surface and decreases
FT                   autoinhibition conformation."
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT   MUTAGEN         362
FT                   /note="K->E: Increases constitutive kinase activity on LAT
FT                   phosphorylation, strongly increases subcellular
FT                   localization of CD69 at the cell surface and decreases
FT                   autoinhibition conformation."
FT                   /evidence="ECO:0000269|PubMed:26783323"
FT   MUTAGEN         461
FT                   /note="D->N: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         479
FT                   /note="D->N: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15292186"
FT   MUTAGEN         492
FT                   /note="Y->F: Increases kinase activity."
FT                   /evidence="ECO:0000269|PubMed:7781602"
FT   MUTAGEN         493
FT                   /note="Y->F: Impairs kinase activity."
FT                   /evidence="ECO:0000269|PubMed:7781602"
FT   MUTAGEN         538
FT                   /note="K->R: No effect on ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:26903241"
FT   MUTAGEN         544
FT                   /note="K->R: Strongly decreased ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:26903241"
FT   MUTAGEN         597
FT                   /note="Y->A: Increased kinase activity after activation by
FT                   LCK."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   MUTAGEN         598
FT                   /note="Y->A: Increased kinase activity after activation by
FT                   LCK."
FT                   /evidence="ECO:0000269|PubMed:17512407"
FT   TURN            4..7
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          11..14
FT                   /evidence="ECO:0007829|PDB:1M61"
FT   HELIX           17..26
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          34..38
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          40..42
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          46..52
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          55..63
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          69..71
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           80..89
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          94..96
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           114..131
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           135..156
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           157..160
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           170..178
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   TURN            179..181
FT                   /evidence="ECO:0007829|PDB:1M61"
FT   STRAND          186..191
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          197..204
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          207..215
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   TURN            217..219
FT                   /evidence="ECO:0007829|PDB:4XZ1"
FT   STRAND          221..223
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          229..231
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           232..241
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   STRAND          246..248
FT                   /evidence="ECO:0007829|PDB:2OQ1"
FT   HELIX           309..311
FT                   /evidence="ECO:0007829|PDB:4K2R"
FT   STRAND          316..320
FT                   /evidence="ECO:0007829|PDB:2OZO"
FT   HELIX           322..326
FT                   /evidence="ECO:0007829|PDB:4K2R"
FT   HELIX           334..336
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   STRAND          337..345
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   STRAND          350..357
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   STRAND          364..371
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           377..392
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   STRAND          401..415
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           422..426
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   TURN            430..432
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           435..454
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   STRAND          467..471
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   STRAND          474..477
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   TURN            482..485
FT                   /evidence="ECO:0007829|PDB:2OZO"
FT   HELIX           503..505
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           508..513
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           518..533
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   TURN            534..536
FT                   /evidence="ECO:0007829|PDB:4K2R"
FT   TURN            539..542
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           546..553
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           566..574
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           580..582
FT                   /evidence="ECO:0007829|PDB:1U59"
FT   HELIX           586..601
FT                   /evidence="ECO:0007829|PDB:1U59"
SQ   SEQUENCE   619 AA;  69872 MW;  D1E1A8EC66FA116F CRC64;
     MPDPAAHLPF FYGSISRAEA EEHLKLAGMA DGLFLLRQCL RSLGGYVLSL VHDVRFHHFP
     IERQLNGTYA IAGGKAHCGP AELCEFYSRD PDGLPCNLRK PCNRPSGLEP QPGVFDCLRD
     AMVRDYVRQT WKLEGEALEQ AIISQAPQVE KLIATTAHER MPWYHSSLTR EEAERKLYSG
     AQTDGKFLLR PRKEQGTYAL SLIYGKTVYH YLISQDKAGK YCIPEGTKFD TLWQLVEYLK
     LKADGLIYCL KEACPNSSAS NASGAAAPTL PAHPSTLTHP QRRIDTLNSD GYTPEPARIT
     SPDKPRPMPM DTSVYESPYS DPEELKDKKL FLKRDNLLIA DIELGCGNFG SVRQGVYRMR
     KKQIDVAIKV LKQGTEKADT EEMMREAQIM HQLDNPYIVR LIGVCQAEAL MLVMEMAGGG
     PLHKFLVGKR EEIPVSNVAE LLHQVSMGMK YLEEKNFVHR DLAARNVLLV NRHYAKISDF
     GLSKALGADD SYYTARSAGK WPLKWYAPEC INFRKFSSRS DVWSYGVTMW EALSYGQKPY
     KKMKGPEVMA FIEQGKRMEC PPECPPELYA LMSDCWIYKW EDRPDFLTVE QRMRACYYSL
     ASKVEGPPGS TQKAEAACA
//
